Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two
Authors:
- Y. ChenYCY. Chen
- F. DanehyFDF. Danehy
- K. DufuKDK. Dufu
- J. EkstromJEJ. Ekstrom
- E. GetmanovaEGE. Getmanova
- J. GokemeijerJGJ. Gokemeijer
- L. XuLXL. Xu
- D. LipovsekDLD. Lipovsek
Open Access
- 8 August 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Protein Engineering, Design and Selection
- Vol. 18 (9) , 435-444
Abstract
The tenth human fibronectin type three domain (10Fn3) is a small (10 kDa), extremely stable and soluble protein with an immunoglobulin-like fold, but without cysteine residues. Selections from 10Fn3-based libraries of proteins with randomized loops have yielded high-affinity, target-specific antibody mimics. However, little is known about the biophysical properties of such antibody mimics, which will determine their suitability for in vitro and medical applications. We characterized target binding and biophysical properties of two related 10Fn3-based antibody mimics that bind vascular endothelial growth factor receptor two (VEGF-R2). The first antibody mimic, which has a dissociation constant (Kd) of 13 nM, is highly stable [melting temperature (Tm) = 62°C] and soluble, whereas the second, which binds VEGF-R2 with 40× higher affinity, is less stable (Tm < 40°C) and relatively insoluble. We used our understanding of these two 10Fn3 derivatives and of wild-type 10Fn3 structure to engineer the next generation of antibody mimics, which have an improved combination of high affinity (Kd = 0.59 nM), stability (Tm = 53°C) and solubility. Our findings illustrate that 10Fn3-based antibody mimics can be engineered for favorable biophysical properties even when 20% of the wild-type 10Fn3 sequence is mutated in order to satisfy target-binding requirements.Keywords
This publication has 57 references indexed in Scilit:
- Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of a fibronectin type III domainProtein Engineering, Design and Selection, 2002
- β-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the CamelidaeAntimicrobial Agents and Chemotherapy, 2001
- Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinityProceedings of the National Academy of Sciences, 2000
- Probing the importance of second sphere residues in an esterolytic antibody by phage displayJournal of Molecular Biology, 1998
- Long-acting Growth Hormones Produced by Conjugation with Polyethylene GlycolJournal of Biological Chemistry, 1996
- High Level Expression and Rational Mutagenesis of a Designed Protein, the MinibodyJournal of Molecular Biology, 1994
- Proposed acquisition of an animal protein domain by bacteria.Proceedings of the National Academy of Sciences, 1992
- Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem.Proceedings of the National Academy of Sciences, 1992
- Making antibody fragments using phage display librariesNature, 1991
- Plasma fibronectin concentration in patients with acquired consumptive coagulopathiesThrombosis Research, 1984